Stockscreener 앱 받기
14.53
0.41%
0.06
시장 영업 전:
14.78
0.25
+1.72%
전일 마감가:
$14.47
열려 있는:
$14.48
하루 거래량:
2.89M
Relative Volume:
1.91
시가총액:
$1.43B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-30.91
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-16.97%
1개월 성능:
-17.26%
6개월 성능:
+20.88%
1년 성능:
+7.31%
1일 변동 폭
$14.26
$14.91
1주일 범위
$14.26
$17.54
52주 변동 폭
$10.01
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
14.53 | 1.43B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Moving Average Crossover Confirms Uptrend in ARS Pharmaceuticals Inc.Weekly Investment Summary & Verified Short-Term Plans - beatles.ru
Will ARS Pharmaceuticals Inc. Benefit From Sector TailwindsMarket Risk Analysis & Stepwise Trade Signal Implementation - newsyoung.net
ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - simplywall.st
ARS Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
Is ARS Pharmaceuticals Inc. the Top Chart Pick This Week2025 Trading Recap & Safe Entry Momentum Stock Tips - sundaytimes.kr
ARS Pharmaceuticals Plunges 9.23%—What's Unraveling in the Lab? - AInvest
ARS Pharmaceuticals is Now Oversold (SPRY) - Nasdaq
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales - Investing.com
ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets - MSN
ARS Pharma Sales Jump 3,040% in Q2 - AOL.com
ARS Pharmaceuticals Reports Strong Growth for neffy - TipRanks
ARS Pharmaceuticals 2025 Q2 Earnings Sharp Revenue Surge Amid Widening Losses - AInvest
ARS Pharmaceuticals shares rise 1.07% after-hours after reporting Q2 revenue of $15.7 million and global expansion of neffy. - AInvest
ARS Pharma Sales Jump 3,040% in Q2 - The Motley Fool
ARS Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals' Q2 2025: Navigating Key Contradictions in DTC Impact, Inventory, and NUCLEUS Commercialization - AInvest
ARS Pharmaceuticals reports reports Q2 EPS (46c), consensus (51c) - TipRanks
SPRY Plummets 11.5%: What's Behind the Sharp Decline? - AInvest
Transcript : ARS Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
ARS Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q2 2025 revenue beats forecast - Investing.com
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises - MarketScreener
ARS Pharmaceuticals earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
ARS Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q2 Revenue $15.7M, vs. FactSet Est of $13.8M - MarketScreener
ARS Pharmaceuticals Reports Second Quarter 2025 Financial - GlobeNewswire
ARS Pharmaceuticals Posts $15.7 Million Q2 Revenue, Neffy Sales Reach $12.8 Million in US. - AInvest
ARS Pharma (SPRY) 8-K: Q2 Results & Updated Investor Presentation Filed | SPRY SEC FilingForm 8-K - Stock Titan
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - Yahoo Finance
TR | OpenAI4o Maintains ARS Pharmaceuticals(SPRY.US) With Hold Rating, Cuts Target Price to $16.5 - 富途牛牛
What drives ARS Pharmaceuticals Inc.’s stock priceShort-Term Explosive Growth - 선데이타임즈
What ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) 26% Share Price Gain Is Not Telling You - 富途牛牛
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
ARS Pharmaceuticals SPRY 2025Q2 Earnings Preview Upside Potential Amid Strategic Developments - AInvest
What are the risks of holding ARS Pharmaceuticals Inc.Maximum Return Portfolio Ideas - thegnnews.com
ARS Pharmaceuticals: Pioneering a Needle-Free Revolution in Allergy Treatment - AInvest
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13. - AInvest
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
What makes ARS Pharmaceuticals Inc. stock price move sharplyHigh-profit capital plays - Jammu Links News
How does ARS Pharmaceuticals Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):